| scholarly article | Q13442814 |
| P50 | author | Svetlana D. Pack | Q55716436 |
| Frederic G. Barr | Q112547144 | ||
| Stephen M. Hewitt | Q30361876 | ||
| P2093 | author name string | Wenyue Sun | |
| Mary E Olanich | |||
| Zied Abdullaev | |||
| P2860 | cites work | Cell cycle control as a promising target in melanoma | Q38318198 |
| Identification of target genes of the p16INK4A-pRB-E2F pathway. | Q38351396 | ||
| Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo | Q38974966 | ||
| Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy | Q39446630 | ||
| Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells | Q40274503 | ||
| Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. | Q40866307 | ||
| Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. | Q40877476 | ||
| Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. | Q40898192 | ||
| Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group | Q41842448 | ||
| Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein | Q42831049 | ||
| Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma | Q47733005 | ||
| Identification of a cellular transcription factor involved in E1A trans-activation | Q48366187 | ||
| Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. | Q54434638 | ||
| Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. | Q54721888 | ||
| Human myoblasts and muscle-derived SP cells | Q60178218 | ||
| Defining the substrate specificity of cdk4 kinase-cyclin D1 complex | Q74589698 | ||
| Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR | Q81352887 | ||
| Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor | Q81589836 | ||
| Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry | Q82161721 | ||
| Fluorescence in situ hybridization : application in cancer research and clinical diagnostics | Q83405911 | ||
| A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells | Q24297823 | ||
| Cell cycle, CDKs and cancer: a changing paradigm | Q24314465 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase | Q24554436 | ||
| Cellular senescence and tumor suppressor gene p16 | Q24629853 | ||
| E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes | Q24633900 | ||
| Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer | Q27851620 | ||
| Cell cycle kinases as therapeutic targets for cancer | Q28250447 | ||
| Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas | Q28255510 | ||
| Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances | Q28289157 | ||
| The lac operator-repressor system is functional in the mouse | Q28366874 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma | Q30426051 | ||
| Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling | Q30563970 | ||
| MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data | Q31004603 | ||
| Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005 | Q34192795 | ||
| Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma | Q34334974 | ||
| Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma | Q34341396 | ||
| The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo | Q34621429 | ||
| Coordinated regulation of life and death by RB. | Q35058588 | ||
| E2F target genes: unraveling the biology | Q35884915 | ||
| Subunit composition determines E2F DNA-binding site specificity | Q36573886 | ||
| CDK4: A Key Player in the Cell Cycle, Development, and Cancer | Q36796424 | ||
| Activation of a preexisting cellular factor as a basis for adenovirus E1A-mediated transcription control | Q37482201 | ||
| Molecular and cellular biology of rhabdomyosarcoma. | Q37630588 | ||
| A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. | Q38083828 | ||
| Signaling through cyclin D-dependent kinases | Q38104238 | ||
| The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma | Q38148748 | ||
| Molecular pathways: CDK4 inhibitors for cancer therapy | Q38209308 | ||
| E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. | Q38304702 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rhabdomyosarcoma | Q1898141 |
| P304 | page(s) | 4947-4959 | |
| P577 | publication date | 2015-03-25 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma | |
| P478 | volume | 21 |
| Q58609752 | A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma |
| Q47384424 | CDK4 expression in chordoma: A potential therapeutic target |
| Q33759276 | CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest |
| Q38723383 | CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. |
| Q37693690 | Cell cycle proteins as promising targets in cancer therapy |
| Q92542126 | Current and Future Treatment Strategies for Rhabdomyosarcoma |
| Q52579552 | Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. |
| Q96172104 | Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies |
| Q47294507 | Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells. |
| Q93384341 | Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review |
| Q55710176 | Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. |
| Q38718679 | PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma |
| Q92796910 | Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma |
| Q38371672 | Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. |
| Q58109286 | Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma |
| Q64099630 | Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target |
| Q38794109 | Treating cancer with selective CDK4/6 inhibitors |
Search more.